EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. “This special dividend reflects our commitment to creatin ...

Argenx SE ARGX stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).The study met its primary endpoint, demonstrating that AChR-Ab seronegative gMG patients treated with Vyvgart achieved a statistically significant and clinically meaningful improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living) total score compared to placebo.Argenx plans to submit a supplemental ...

Core Viewpoint - Eli Lilly and Co. has experienced significant stock volatility due to developments in its weight-loss drug portfolio, with recent positive trial results boosting investor confidence [1][5]. Company Summary - Eli Lilly's stock reached highs near $960 in August 2024 but subsequently dropped over 20% due to disappointing drug trial results and concerns regarding insurance coverage and competition [2]. - The company's oral obesity drug previously failed to meet expectations compared to rival products, prompting investors to reassess growth prospects [3]. - Increased competition in the obesity drug market has led to price wars, creating further uncertainty for Eli Lilly [4]. Market Reaction - Following the announcement of positive Phase 3 trial results, Eli Lilly's stock surged more than 4%, indicating renewed investor confidence in the drug's regulatory and commercial potential [5]. - At the time of publication, Eli Lilly shares were reported at $724.66, reflecting a 4.22% increase [5].

After five months of price weakness, AbbVie (NYSE: ABBV ) has seen a strong August, with 11.4% MoM gains so far. As a result, it has risen by 16.6% YTD, a big jump from the just 3.8% YTD increase it had seen when IManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants ...

After a surprise rejection, Cosmo’s acne cream Winlevi wins EU regulator backing — with limits on teen use https://t.co/g1vZ6l81wG ...

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill. https://t.co/57DKN32qpC ...

Core Viewpoint - Catalyst Pharmaceuticals (CPRX) has entered into a settlement agreement with Lupin Pharmaceuticals regarding patent litigation over Firdapse, which protects the company's sales from generic competition until February 25, 2035 [1][5][6]. Group 1: Firdapse Overview - Firdapse is approved in the U.S., EU, and Japan for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and has recently expanded its label to include pediatric patients aged six and older [2]. - In 2024, Firdapse accounted for 62% of Catalyst Pharmaceuticals' sales, generating $168.6 million in revenue in the first half of 2025 [5][8]. Group 2: Settlement Details - The settlement prohibits Lupin from marketing its generic version of Firdapse in the U.S. before February 25, 2035, unless specific exceptions arise [6]. - The agreement also resolves all ongoing patent litigation between Catalyst Pharmaceuticals/SERB and Lupin in the U.S. District Court in New Jersey [6][7]. Group 3: Other Products and Market Position - Catalyst Pharmaceuticals markets two additional drugs in the U.S.: Fycompa for epilepsy and Agamree for Duchenne muscular dystrophy, which provide incremental revenue [9]. - The patents for Fycompa are set to expire in 2025 and 2026, leading to anticipated declines in sales due to increased competition from generics [10].

Economic Indicators - Durable Goods Orders for July decreased by -2.8%, an improvement from the consensus estimate of -4.0% and the previous month's -9.4%, which was the lowest since April 2020 [2] - Excluding Transportation orders, Durable Goods Orders increased by +1.1%, the highest since September of the previous year [3] - Shipments of Durable Goods showed a +0.7% increase, marking the strongest performance of 2025 so far [3] Housing Market - Case-Shiller Home Prices for June rose by +2.1%, which is 20 basis points below expectations and down from +2.8% in May, representing the lowest level since July 2023 [4] - Year-over-year Housing Wealth increased by +1.9%, which is below the inflation rate of +2.7% in June [4] - New York City saw a +7.0% increase in housing value over the past year, while Tampa, San Francisco, and Dallas experienced declines of -2.4%, -2.0%, and -1.0% respectively [5] Company News - Eli Lilly reported a -10.5% average reduction in body weight from its phase-3 testing of a new weight loss pill, with shares up +2.5% following the announcement [6] - The Bank of Montreal (BMO) exceeded earnings expectations by +9.9%, reporting $2.33 per share compared to the consensus of $2.12, while The Bank of Nova Scotia (BNS) reported a +7% earnings beat at $1.37 per share versus the expected $1.28 [7]

Core Insights - Immuneering Corporation (IMRX) has entered into a clinical supply agreement with Eli Lilly (LLY) for the KRAS G12C inhibitor, olomorasib (LY3537982) [1] - The agreement supports a planned phase II study evaluating Immuneering's atebimetinib (IMM-1-104) in combination with olomorasib for treating advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) [2] - Immuneering's shares rose by 21.7% following the announcement, and the stock has increased by 170.5% year-to-date compared to the industry's 4.1% rise [2][3] Agreement Details - The combination of atebimetinib and olomorasib is expected to provide a vertical blockade of the RAS-MAPK pathway, with preclinical data showing enhanced tumor regression and prolonged survival compared to monotherapy [5] - This is Immuneering's second collaboration announcement in 2025, following a similar agreement with Regeneron Pharmaceuticals to evaluate atebimetinib with Libtayo for advanced NSCLC [6][7] - In both agreements, Immuneering retains full worldwide development and commercialization rights to atebimetinib [8] Ongoing Studies - Immuneering is advancing atebimetinib in other cancer studies, including a phase IIa study in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer [9] - Preliminary data from this study indicated a 94% overall survival and 72% progression-free survival at six months, with updated data expected later in Q3 2025 [10] - The company plans to initiate a pivotal study for atebimetinib in combination with modified gemcitabine/nab-paclitaxel in 2026, pending regulatory feedback [11]

Core Insights - Novo Nordisk (NVO) has faced a significant setback in July, reducing its 2025 sales and profit outlook due to slower-than-expected growth in its semaglutide-based drugs, Wegovy and Ozempic, particularly in the U.S. obesity market [1] - The company is working to diversify its revenue sources beyond GLP-1 drugs, focusing on its Rare Disease franchise, which has seen notable regulatory milestones [2] - The FDA granted accelerated approval for Wegovy to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), marking a significant advancement in liver care [3] Sales and Market Performance - Eli Lilly's GLP-1 therapies, Mounjaro and Zepbound, have rapidly gained market share, generating combined sales of $14.7 billion in the first half of 2025, accounting for 52% of Eli Lilly's total revenues [4] - Novo Nordisk's stock has underperformed, losing 34.5% year-to-date compared to a 0.3% decline in the industry [6][8] Regulatory Developments - Novo Nordisk has received EU approval for Alhemo to treat hemophilia A and B, enhancing its Rare Disease portfolio [2][8] - Wegovy is now the first GLP-1 therapy approved for MASH, providing a new treatment option for patients with liver disease [3][8] Financial Estimates and Valuation - Earnings estimates for 2025 have decreased from $3.98 to $3.84 per share, while 2026 estimates have dropped from $4.56 to $4.09 [12] - Novo Nordisk's shares are trading at a price/earnings ratio of 14.07, lower than the industry average of 14.85 and significantly below its five-year mean of 29.25 [9]